Efficacy and Safety Study of Dexmedetomidine as an Additive to Local Anesthetics in Shoulder Surgery
The purpose of this study is to test the efficacy and safety of dexmedetomidine added to ropivacaine in patients undergoing shoulder surgery.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)
Primary Purpose: Treatment
|Official Title:||The Efficacy and Safety of Dexmedetomidine as an Additive to Ropivacaine for Interscalene Brachial Plexus Blocks for Shoulder Surgery|
- Efficacy of dexmedetomidine in perineural application [ Time Frame: 24 hrs ] [ Designated as safety issue: No ]The time until the patient describes the blockade as completely gone will be analysed and compared between the groups.
- Safety of dexmedetomidine in perineural application [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]Any serious and/or unexpected adverse (AE) events will be assessed on an individual basis by the Principal Investigator and the DSMB. After the first twenty subjects (10 controls and 10 receiving study agent) have completed the study, the data will be reviewed. Provided the DSMB determines the initial safety is established, enrollment will proceed until a total of 62 subjects (31 subjects/group) have been accrued.
- Analgesia [ Time Frame: first 24-48 hrs ] [ Designated as safety issue: No ]Analgesia will be assessed based on postoperative pain scores
- Onset of sensory blockade [ Time Frame: every 3 minutes for the first 21 minutes ] [ Designated as safety issue: No ]The subject's sensory function will be measured every 2 minutes for the first 20 minutes, until the loss of sensory function in the dermal distribution of the shoulder.
- Duration of motor blockade [ Time Frame: first 24-48 hrs ] [ Designated as safety issue: No ]The time to return of motor strength will be recorded in the subject's postoperative course.
- Opioid-induced side effects [ Time Frame: first 24-48 hrs ] [ Designated as safety issue: No ]Opioid-induced side effects will be recorded in the subject's postoperative course.
|Study Start Date:||March 2012|
|Study Completion Date:||November 2012|
|Primary Completion Date:||November 2012 (Final data collection date for primary outcome measure)|
Experimental: ropivacaine + dexmedetomidine
This group represents the standard of care drug (ropivacaine) plus the new additive to be studied (dexmedetomidine)
ropivacaine 100 mg + 150 mcg dexmedetomidine, single shot perineural application
Active Comparator: ropivacaine + saline
This group represents the current standard of care in peripheral nerve blockade
ropivacaine + saline placebo, single shot perineural application
Peripheral nerve blocks are used throughout the world in lieu of general anesthesia and, more commonly, to provide analgesia and opioid sparing in the postoperative course. Long acting local anesthetics, such as ropivacaine, can provide analgesia for 11.5 ± 5 hours. This leads to many patients reporting their first pain in the evening and nighttime hours when access to healthcare providers and support is most limited. A number of additives to local anesthetics have been studied in humans with limited success. Recent work by a group in Michigan found a dose dependent increase in the duration of analgesia to a thermal stimulus when dexmedetomidine was added to ropivacaine for sciatic nerve blocks in rat.
The goal of the study is to investigate the safety and efficacy of dexmedetomidine added to ropivacaine for interscalene brachial plexus nerve block for shoulder surgery in humans. Provided the initial safety can be established, the trial will continue to evaluate secondary goals including the duration of analgesia, onset of sensory and motor blockade, and opioid-induced side effects. Tertiary outcomes will include subject satisfaction.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01557270
|Paracelsus Medical University, Department of Anesthesiology, Perioperative and Intensive Care Medicine|
|Salzburg, Austria, 5020|
|Principal Investigator:||Peter Gerner, MD||Paracelsus Medical University Salzburg, Department of Anesthesiology|